{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T11:41:51Z","timestamp":1744458111657},"reference-count":44,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2022,6,15]]},"DOI":"10.18632\/oncotarget.28244","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T17:18:27Z","timestamp":1655313507000},"page":"812-827","source":"Crossref","is-referenced-by-count":3,"title":["Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program"],"prefix":"10.18632","volume":"13","author":[{"given":"Reyes","family":"Bernab\u00e9-Caro","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hospital Virgen del Roc\u00edo, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Garrido","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Garc\u00eda-Campelo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario A Coru\u00f1a, A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Palmero","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, ICO Bellvitge, Hospitalet Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Artal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Bayona","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital General Yague, Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delvys","family":"Rodr\u00edguez-Abreu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"L\u00f3pez-Brea","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Paredes","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Donostia, Donostia-San Sebasti\u00e1n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Vicente","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Virgen Macarena, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Miguel","family":"S\u00e1nchez Torres","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario La Princesa, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Majem","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Diz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Complejo Asistencial Universitario de Le\u00f3n, Le\u00f3n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Gordo","sequence":"additional","affiliation":[{"name":"Roche Farma, S.A., Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Coca","sequence":"additional","affiliation":[{"name":"Roche Farma, S.A., Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"de Castro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"44","author":"Ishikawa","year":"2007","journal-title":"Nature"},{"key":"2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1200\/JCO.2015.62.0138","article-title":"Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis","volume":"3","author":"Kavanagh","year":"2016","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"8","author":"Costa","year":"2015","journal-title":"Lung Cancer"},{"key":"4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10555-015-9592-y","article-title":"Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?","volume":"3","author":"Ichinose","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"5","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"37","author":"Wilner","year":"2014","journal-title":"N Engl J Med"},{"key":"6","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"36","author":"O\u2019Byrne","year":"2013","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"1","author":"Tang","year":"2016","journal-title":"Lancet Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial","volume":"1","author":"Gold","year":"2016","journal-title":"Lancet Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jtho.2017.06.070","article-title":"Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer","volume":"1","author":"Ahn","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.lungcan.2019.10.015","article-title":"Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer","volume":"13","author":"Dansin","year":"2020","journal-title":"Lung Cancer"},{"key":"11","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study","volume":"2","author":"Johannsdottir","year":"2018","journal-title":"Ann Oncol"},{"key":"12","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1016\/j.jtho.2019.08.416","article-title":"OA02.07 Phase 3 ALUR Study of Alectinib in Pretreated ALK+ NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses","volume":"1","author":"Novello","year":"2019","journal-title":"J Thorac Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"37","author":"Golding","year":"2017","journal-title":"N Engl J Med"},{"key":"14","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","article-title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study","volume":"2","author":"N\u00fcesch","year":"2018","journal-title":"Ann Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"9043","DOI":"10.1200\/JCO.2018.36.15_suppl.9043","article-title":"Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC","volume":"3","author":"Mitry","year":"2018","journal-title":"J Clin Oncol"},{"key":"16","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study","volume":"1","author":"Moro-Sibilot","year":"2019","journal-title":"J Thorac Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"3","author":"Hilton","year":"2020","journal-title":"Ann Oncol"},{"key":"18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"39","author":"Goto","year":"2017","journal-title":"Lancet"},{"key":"19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.lungcan.2019.11.025","article-title":"Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"13","author":"Watanabe","year":"2020","journal-title":"Lung Cancer"},{"key":"20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study","volume":"7","author":"Wang","year":"2019","journal-title":"Lancet Respir Med"},{"key":"21","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.2217\/fon-2018-0027","article-title":"The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer","volume":"1","author":"Gadgeel","year":"2018","journal-title":"Future Oncol"},{"key":"22","unstructured":"European Medicines Agency. Alecensa (Alectinib). 2018. Available from: https:\/\/www.ema.europa.eu\/medicines\/human\/EPAR\/alecensa (Accessed 09\/October\/2018)."},{"key":"23","unstructured":"NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-Small Cell Lung Cancer, Version 1.2022. Available online: https:\/\/www.nccn.org."},{"key":"24","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"2","author":"Peters","year":"2018","journal-title":"Ann Oncol"},{"key":"25","unstructured":"NCCN. Guidelines, Non-small Cell Lung Cancer, version 4. 2021. https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/lung-early-stage-patient.pdf."},{"key":"26","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1158\/1078-0432.CCR-09-0802","article-title":"Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population","volume":"1","author":"Johnson","year":"2009","journal-title":"Clin Cancer Res"},{"key":"27","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fonc.2020.01299","article-title":"Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients","volume":"1","author":"Curioni-Fontecedro","year":"2020","journal-title":"Front Oncol"},{"key":"28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/03007995.2018.1533458","article-title":"Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients","volume":"3","author":"Crane","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"29","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1007\/s12325-020-01392-0","article-title":"Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study","volume":"3","author":"Ohe","year":"2020","journal-title":"Adv Ther"},{"key":"30","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1634\/theoncologist.2020-0011","article-title":"Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer","volume":"2","author":"Socinski","year":"2020","journal-title":"Oncologist"},{"key":"31","doi-asserted-by":"publisher","first-page":"100571","DOI":"10.1016\/j.currproblcancer.2020.100571","article-title":"Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India","volume":"4","author":"Khurana","year":"2020","journal-title":"Curr Probl Cancer"},{"key":"32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40801-020-00207-6","article-title":"Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer","volume":"7","author":"Masters","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"33","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1093\/ejcts\/ezv371","article-title":"Immunotherapy for non-small cell lung cancer: current concepts and clinical trials","volume":"4","author":"Adusumilli","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"34","doi-asserted-by":"publisher","first-page":"ii52","DOI":"10.1093\/annonc\/mdz063.037","article-title":"Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States","volume":"3","author":"Jahanzeb","year":"2019","journal-title":"Ann Oncol"},{"key":"35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cllc.2020.08.003","article-title":"Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer","volume":"2","author":"Langer","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"36","unstructured":"European Medicines Agency. Zykadia (ceritinib). 2019. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zykadia."},{"key":"37","unstructured":"European Medicines Agency. Alunbrig (brigatinib). 2019. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alunbrig."},{"key":"38","unstructured":"European Medicines Agency. Lorviqua (lorlatinib). 2019. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lorviqua."},{"key":"39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.6004\/jnccn.2021.0013","article-title":"NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021","volume":"1","author":"Gettinger","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"40","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","article-title":"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial","volume":"1","author":"Rivera","year":"2016","journal-title":"Lancet Oncol"},{"key":"41","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"1","author":"Martini","year":"2017","journal-title":"Lancet Oncol"},{"key":"42","doi-asserted-by":"publisher","first-page":"21903","DOI":"10.18632\/oncotarget.15746","article-title":"Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study","volume":"8","author":"Otto","year":"2017","journal-title":"Oncotarget"},{"key":"43","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","article-title":"Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases","volume":"3","author":"Wiltshire","year":"2015","journal-title":"J Clin Oncol"},{"key":"44","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2016.68.4639","article-title":"Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer","volume":"3","author":"De Pas","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T17:18:35Z","timestamp":1655313515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,6,15]]}},"alternative-id":["28244"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28244","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]}}}